Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS by McDonnell, T et al.
METHODOLOGY ARTICLE Open Access
Development of a high yield expression
and purification system for Domain I of
Beta-2-glycoprotein I for the treatment of APS
Thomas McDonnell1*, Charis Pericleous1, Emmanuelle Laurine2, Rita Tommasi2, Acely Garza-Garcia3, Ian Giles1,
Yiannis Ioannou1,4 and Anisur Rahman1
Abstract
Background: In this paper we describe a novel method to achieve high yield bacterial expression of a small protein
domain with considerable therapeutic potential; Domain I of Beta-2-glycoprotein I (β2GPI). β2GPI is intrinsic to the
pathological progression of the Antiphospholipid Syndrome (APS). Patients develop autoantibodies targeting an
epitope located on the N-terminal Domain I of β2GPI rendering this domain of interest as a possible therapeutic.
Results: This new method of production of Domain I of β2GPI has increased the production yield by ~20 fold
compared to previous methods in E.coli. This largely scalable, partially automated method produces 50–75 mg of pure,
folded, active Domain I of β2GPI per litre of expression media.
Conclusion: The application of this method may enable production of Domain I on sufficient scale to allow its use as a
therapeutic.
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Background
Protein-based biologic agents are increasingly used in
the treatment of a range of autoimmune diseases. They
may exert their effects by blocking receptor-ligand or
antibody-antigen interactions or by delivering an exogen-
ous enzyme such as uricase [1–5]. It is necessary however,
to modify small proteins in order to create optimal
therapeutic agents in particular to increase their in-vivo
half-life and reduce their immunogenicity. PEGylation is
one of the main methods used to achieve this and
PEGylated proteins currently used in clinical practice
include Puricase® (PEG-uricase) for gout [2, 6], PegIntron®/
PEGASYS® (PEG-Interferon alpha) for hepatitis C and
myeloid leukemia [7, 8] and Cimzia® (certolizumab pegol)
for rheumatoid arthritis [9–11]. The production of pure ac-
tive PEGylated protein requires significant amounts of na-
tive human protein as raw material for PEGylation and
extraction of these amounts from blood samples of
human volunteers is not feasible. It is therefore crit-
ical to obtain large scale production of recombinant
soluble, folded protein to be used as starting material for
PEGylation. Mammalian, insect, yeast and bacterial expres-
sion systems could all be used to approach this goal.
The advantages of heterologous protein expression in
Escherichia coli are many fold: (I) the technique is well
studied and established, (II) yields per volume of culture
are potentially very high, (III) the materials and carbon
sources needed for cell growth and protein expression
are inexpensive and, (IV) a variety of E coli-expressed
proteins suitable for human use have already been com-
mercialised [12–14]. There are, however, also significant
drawbacks to bacterial expression. One of the most sig-
nificant is that recombinant proteins are often misfolded
and/or aggregated and found in insoluble particles called
inclusion bodies. Refolding aggregated protein is a com-
plex process resulting in low yields [15, 16]. Another limi-
tation of expression in the bacterial cytoplasm is the
impossibility of obtaining proteins with post-translational
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modifications such as disulphide bond formation or glyco-
sylation. In some cases, this limitation can be circum-
vented by directing the expression product to the bacterial
periplasm where some post-translational modifications
naturally occur. Also, advances have been made in the
design of genetically engineered bacterial strains with
enhanced post-translational modification capabilities
[17–19]. The final consideration when proteins are pro-
duced in E. coli is contamination of the purified protein
with Gram-negative bacterial cell wall components.
The presence of these endotoxins precludes the use of
the preparation in vivo or for cell culture studies.
Mammalian cell expression has some advantages over
bacterial expression, mainly lack of endotoxin contamin-
ation and production of proteins with native or near-
native post-translational modifications. Yields tend to be
lower than in bacterial expression, but methods have
been developed to increase them [20], The main disad-
vantages of expression in mammalian cells are that it
requires very specialised equipment [20, 21] is expensive
-at least in a bench top scale-, and expression levels rely
heavily on a random integration process [21]. Similarly
some groups use insect cells and yeasts such as Pichia
pastoris. However, these systems are less well-developed,
can be delicate to manipulate, lower yields are frequent
and yeast tends to generate escape mutants in culture
[22]. It is for these reasons, cost, efficiency, flexibility
and convenience, that most often laboratory protein ex-
pression prefers to utilize bacterial hosts.
In this paper we describe the development of a novel
method for medium scale bacterial expression of a small
protein domain with considerable therapeutic potential,
the N-terminal domain of beta-2-glycoprotein I (β2GPI),
commonly designated domain I (DI). DI is a critical anti-
gen in the anti-phospholipid syndrome (APS).
APS is an autoimmune disease characterised by vascular
thrombosis and/or recurrent miscarriages in patients and
is a significant cause of mortality and morbidity. It is also
the leading cause of strokes in patients under 50 years of
age [23–25]. The disease is characterised by the presence
of a heterogeneous population of auto-antibodies [26] that
bind a range of antigens, in particular beta-2-glycoprotein
I (β2GPI) [25, 27–29]. Anti-β2GPI antibodies have been
closely associated with thrombosis implying a significant
role of these antibodies in the pathogenesis of the disease
[30, 31]. Current treatment for APS patients is long-term
anticoagulation with warfarin or heparin, which are a
non-specific vitamin K dependent coagulation blocking
agent and an activator of anti-thrombin III respectively.
These treatments lack efficacy in some cases and carry a
significant risk of side-effects such as haemorrhage [32].
There is thus a pressing need to develop new targeted ther-
apies such as drugs that would inhibit binding of anti-
β2GPI antibodies to β2GPI. The critical pathogenic epitope
of β2GPI [25, 29, 33, 34] has been defined as a conform-
ational epitope covering residues 8 and 9 and 39–43 on
DI. Recombinant DI inhibits the binding of antibodies
derived from APS patients to β2GPI in ELISA binding
assay [25]. In vivo studies showed that recombinant
DI inhibits the development of thrombosis in mice
exposed to IgG from patients with APS [23]. DI is
non-glycosylated and is thus ideally suited for bacterial
expression. We have also used recombinant DI as the
substrate in an ELISA to detect serum anti-DI antibodies.
In studies of large numbers of sera from patients with
APS, autoimmune disease controls and healthy controls,
anti-DI positivity enhances the ability to differentiate
patients with APS from other groups (reviewed in
Bertolaccini et al. [35]).
In previously published work we developed two
methods for the expression of DI in E. coli. The yield of
soluble hexa-histidine tagged DI was around 0.75 mg/L
of bacterial culture [36] when the expression product
was targeted to the bacterial periplasm and approxi-
mately 4 mg/L when recovered from inclusion bodies
[37]. Now we present a novel method suitable for
medium-scale production of highly pure human DI in
E.coli, and verify protein activity by ELISA assays show-
ing that the expression product inhibits binding of IgG
from patients with APS to β2GPI.
Methods
All chemicals were purchased from Sigma, unless other-
wise stated.
DI expression vector
The synthetic DI coding sequence as previously pub-
lished [37] was cloned into an in-house modified vector
that incorporates an N-terminal fusion tag consisting of
an hexa-histidine motif for purification and expression, a
BirA biotinylation site and a Factor Xa recognition
sequence for proteolytic cleavage (Fig. 1). These modifi-
cations were introduced into pETHis_1a (a kind gift
from Gunter Stier, then at EMBL Heidelberg), which is
itself a modified pET24d vector (Merck Millipore). The
biotinylation site was introduced during the develop-
ment of the vector to allow the option of binding to
streptavidin-coated plates in ELISA, but we are not
using biotinylated DI for any purpose at present.
Small scale protein expression test in Luria Broth (LB) and
Terrific Broth (TB)
Transformation of BL21*DE3® (Life Technologies) cells
was carried out according to the manufacturer’s instruc-
tions. Cells were plated into LB/agar with kanamycin
50 μg/ml. Single colonies were picked and subcultured
into 3 ml of LB media containing kanamycin (50 μg/ml)
and incubated overnight at 250 rpm and 37 °C. 150 μl of
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preculture were used to inoculate 3 ml of LB or TB and
cells were incubated at 250 rpm and 37 °C; growth was
monitored by OD at 600 nm. For cultures in LB, expres-
sion was induced with 1 mM IPTG at an OD600nm of 0.6.
In order to compare different expression temperatures,
the induced culture was incubated overnight with
shaking at 250 rpm at either 20 °C or 37 °C. For cul-
tures in TB, expression was induced with 1 mM
IPTG at an OD600nm of between 5 and 7. Post induc-
tion, expression was continued overnight with shaking
at 250 rpm at 20 °C. Cells were harvested by centrifuga-
tion for 20 min at 20,000 x g and 4 °C. Pellets were lysed
in 500 μl of 1 % Triton x-100 and 1x PBS, by three cycles
of sonication (output 100, 3 min). Samples were analysed
by SDS PAGE.
Large scale protein expression in TB
A glycerol stock was used to inoculate 200 ml of LB.
Cultures were incubated overnight with shaking at
225 rpm and 37 °C, centrifuged at 3500 × g for 30 min
at room temperature and resuspended in 20 ml of fresh
LB. Two litres of TB were seeded in four 2 L-flasks with
5 ml of pre-culture in each. Expression was then carried
out as for the small scale protocol.
Harvesting
Harvesting was carried out using a 500 kDa Hollow
Fiber Ultrafiltration Cartridge (GE Healthcare). The cell
suspension was run into the cartridge at 100 rpm until a
pellet was formed and the bacterial pellet was further
rinsed by addition of 2 L of PBS. The pellet was trans-
ferred into 50 ml centrifuge tubes, spun at 3,500 × g for
30 min to remove any remaining PBS and finally snap
frozen using dry ice.
Cell lysis and inclusion body solubilisation
Lysis Buffer (A; 50 mM sodium phosphate, 0.3 M Sodium
Chloride, 10 mM Imidazole) was added to the frozen pel-
let with the addition of DNase (0.02 mg/ml) and protease
inhibitors (1:500). Bacterial pellets were suspended by
vortexing and pipette mixing. The lysate was then
sonicated (50 % maximum intensity, 50 % cycles) for
4 min, allowed to cool for 2 min. This was repeated
once. The inclusion bodies were collected by centrifu-
gation of the lysate at 3,500 × g for 30 min. Lighter in-
clusion bodies were harvested by spinning the
supernatant once again at 20,000 × g for 30 min.
Inclusion body preparation
The inclusion bodies were resuspended in Solubilisation
Buffer (B; 6 M guanidine hydrochloride, 0.1 M NaH2PO4,
10 mM Tris, pH 8.0) initially by grinding in a pestle
and mortar homogeniser. The suspension was sonicated
twice for 4 min (50 % maximum intensity, 50 % cycles),
in order to promote protein solubilisation and reduce
viscosity. The suspension was finally centrifuged at
20,000 × g for 20 min to remove insoluble debris prior to
purification.
Purification of denatured protein by immobilised metal
affinity chromatography (IMAC)
The solubilised protein was loaded at 2–5 ml/min
onto a 15-ml HisTrap FF (GE Healthcare) and washed
with 1.5 column volumes (CV) of Denaturing IMAC
Equilibration Buffer (C; 6 M guanidine hydrochloride,
0.1 M NaH2PO4, 10 mM Tris, pH 6.3). The protein
was eluted at 1 ml/min with 2.7 CV of Denaturing
IMAC Elution Buffer (D; 6 M guanidine hydrochloride,
0.1 M NaH2PO4, 10 mM Tris, pH 4.5). The fractions
were collected and analysed by SDS-PAGE. The entire
purification process was conducted on an AKTA platform
(GE Healthcare).
In vitro oxidative protein folding
The protein was pooled and concentrated to 25–30 mg/
ml by centrifugal concentrators. Any potential disul-
phide bonds were reduced by incubating overnight with
50 mM TCEP at 4 °C. TCEP was subsequently removed
by buffer exchange using a PD-10 desalting column (GE
Healthcare). The protein was recovered at a concentra-
tion of >10 mg/ml and was loaded into a 5 ml syringe.
This syringe was fitted into a pump with the tip placed
Sequence Insert Encoding DI and Tag.
Fig. 1 DI fusion protein sequence showing the N-terminal hexa-histidine tag (italics), the BirA recognition site for potential biotinylation (boxed)
and the restriction protease FXa cleavage site (underlined). The cleavage site is indicated with an arrow and the first amino acid of DI is bolded.
The fusion protein is 12.9 kDa while native DI which contains 64 amino acids is 7.2 kDa
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inside 95 mL of the Folding Buffer (E; 0.6 M arginine
hydrochloride, 0.1 M Tris, pH 8.5, 1 mL cysteine
(0.3 M) + 1 mL cystine (0.03 M). The pump was set to
inject constantly at 300 μl/h and left overnight at 4 °C.
The resulting solution was centrifuged at 3,500 × g for
30 min at 4 °C and syringe filtered (25 μm, Sartorius).
The protein solution was further concentrated to ap-
proximately 3–5 mg/ml by Vivaspin® centrifugal ultra-
filtration (5 kDa MWCO, Satorius) and dialysed for 2 h
(3.5 KDa MWCO;, snake skin, thermo scientific)
against 5 L of Native IMAC Equilibration Buffer (F;
20 mM Tris, 0.1 M NaCl, pH 8.0) at 4 °C. Dialysis
buffer was changed after 2 h and the protein was fur-
ther dialysed overnight at 4 °C. The resultant protein
was collected and used for purification by IMAC.
Isolation of folded and monomeric protein by IMAC in
native conditions
Dialysed protein was purified using a 15-ml HisTrap FF
(GE Healthcare) at a flow rate of 2 ml/min. The flow-
through was collected and the column washed with 3–4
CV of Buffer F. The protein was eluted with a gradient
0–100 % Native IMAC Elution Buffer (G; 20 mM Tris,
0.1 M NaCl, 1 M imidazole, pH 8.0) over 8 CV (2 ml/
min). Five millilitre fractions were collected and analysed
by SDS PAGE. The fractions containing recombinant
his-tagged DI were pooled and stored at 4 °C.
Fusion tag cleavage and purification of untagged protein
Purified recombinant tagged DI was dialysed against
PBS (~30 ml in 2 L of PBS for 2 h at 4 °C then the
buffer was exchanged for 2 L of fresh PBS) and freeze-
dried over 48 h in 1 or 2 mg aliquots. Lyophilised
recombinant tagged DI was re-suspended in Cleavage
Buffer (H; 50 mM Tris, 0.1 M NaCl, 1 mM CaCl2,
pH 6.5) and human FXa (Haematologic Technologies)
was added at a ratio of 1:200 to protein (i.e. 1 μg en-
zyme per 200 μg protein), protein concentration was
kept below 1 mg/ml to avoid aggregation. Calcium chlor-
ide was added to a final concentration of 2 mM and the
mixture was incubated without shaking for ~16 h at
22 °C. Samples were analysed by SDS-PAGE to assess
the completion of cleavage.
The cleaved protein was loaded onto a 5 ml HiTrap
SP HP column (GE Healthcare) pre-equilibrated with
3–5 CV of IEX Equilibration Buffer (I; 20 mM HEPES,
pH 6.8). After sample loading the column was further
washed with 3 CV of Buffer I and the sample was
eluted with a 0–100 % linear gradient of IEX Elution
Buffer (J: 20 mM HEPES, 1 M sodium chloride, pH 6.8).
Fractions were collected, analysed by SDS-PAGE and rele-
vant fractions were pooled, dialysed against PBS at 4 °C
(2 L for 2 h, 1 change, and 2 L for 16 h), aliquoted and
freeze dried prior to storage at−80°.
Reverse phase HPLC
Both VariTide RPC (Agilent) and Poroshell C8 (Agilent)
columns were used for RP-HLPC. Ten-μg samples dis-
solved in solvent A were injected and run across either a
4 or a 10 min gradient of 0–100 % solvent B. Solvent A
was 2 % acetonitrile and 0.065 % TFA in ddH2O and
solvent B was 100 % acetonitrile and 0.05 % TFA. Spec-
tra were analysed using Chromeleon® software (Dionex).
Endotoxin removal and quantification
EndoTrap® high capacity columns (Hyglos) were used
for endotoxin removal following the manufacturer’s in-
structions with the following adaptations: protein was
dialysed against PBS overnight before being dialysed into
endotoxin-free PBS via centrifugal ultrafiltration. The
buffer was supplemented with 1 mM calcium chloride.
The EndoLISA® fluorescence assay (Hyglos) was used
for endotoxin quantification following the instructions
of the manufacturer. The amount of endotoxin was
quantified in protein samples at concentrations between
0.1 mg/ml and 2 mg/ml.
Competitive inhibition ELISA
Competitive inhibition ELISA was carried out to test the
ability of recombinant DI to inhibit binding of purified
IgG from patients with APS to immobilised β2GPI. The
assay was adapted from the standard β2GPI ELISA pub-
lished by Ioannou et al. [36] with the following amend-
ments: the inhibitors were pre-incubated at concentrations
ranging from 0 mg/ml to 200 μg/ml rather than 0 to
30 μM. Briefly, the test was carried out to test the ability of
recombinant DI to inhibit binding of purified IgG from pa-
tients with APS to β2GPI coated on a plate. Recombinant
DI was pre-incubated with patient serum prior to addition
on the ELISA plate coated with β2GPI. Bound patient IgG
was detected with an anti-human IgG HRP secondary
antibody. Each sample was tested in duplicate.
Ethical approval for use of samples from patients in
this research was granted by the London Hampstead
Research Ethics Committee Reference Number 12/LO/
0373. Patients gave informed consent for use of their
samples.
Results and discussion
DI fusion protein expression
DI was expressed as a fusion protein containing an add-
itional N-terminal tag including a hexahistidine tag for
purification, a biotinylation site and a FXa cleavage motif
(Fig. 1). A FXa recognition site was chosen over other
more common proteases because no extra amino acids
remain in the recombinant protein after cleavage.
In order to optimise the conditions for the protein ex-
pression preliminary small scale expression tests were per-
formed in 24-well plate format. The following conditions
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Fig. 2 (See legend on next page.)
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were tested: Type of medium (LB or TB), IPTG con-
centration (0.5 mM, 1 mM or 2 mM), length of incu-
bation after induction (8 or 16 h) and temperature of
incubation after induction (20 °C or 37 °C). At the
end of the incubation, bacteria were pelleted, lysed
and the crude extract was analysed by SDS-PAGE in
order to assess the level of protein expression (Fig. 2).
Growth in TB with induction at an OD600 between 5
and 7 with 1 mM IPTG for 16 h 20 °C was selected
as the best condition for the expression of DI fusion
protein (Fig. 2); IPTG at 0.5 mM could also be used
in the future for larger scale production, as within
the tested range, the concentration of IPTG had no
impact on the level of expression. No changes in expres-
sion level were observed when the production was scaled
up to 2 l. Using precultures with an OD600 nm between 0.1
(See figure on previous page.)
Fig. 2 a SDS-PAGE gel comparing crude lysates of small scale expression of tagged Domain I fusion protein in LB and TB media before and after
induction. Recombinant tagged DI fusion is indicated by an arrow and migrates at 12 kDa. Samples were lysed using triton/PBS and diluted in
PBS (5x) and 20 μl was loaded onto an SDS PAGE Gel. The gel was then run, washed briefly in ddH2O and stained for 1 h with InstantBlue™
stain (Expedeon, UK). b & c Densitometric analysis was carried out on LB and TB samples on a small scale loaded in an identical way, gels were
scanned, images converted to TIFF files and analysed. Values represent a calculation of intensity divided by area, OD denotes optical density of
cultures at 600 nm at induction
Fig. 3 a Analysis of denaturing IMAC elution fractions by SDS–PAGE. Samples were diluted 1:8 in water and 15 μl of each dilution were loaded
per well. b An accompanying chromatogram with two peaks highlighted at the bottom. Peak #1 shows no protein on the gel (lanes 5 and 6) as
the amount of this protein was insignificant after dilution to remove guanidine
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and 0.2, the expression would reach induction density
(OD600nm 5–7) within 5 h and reach an overnight
OD600 of approximately 10–13. Bacteria were harvested
by either centrifugation or hollow fiber ultrafiltration.
For convenience and suitability for scaling up, ultrafil-
tration was selected for large scale productions. Typical
expression yields were in the order of 20 g of wet cell
pellet per litre of culture.
DI in vitro folding and purification
Cell lysis and inclusion body solubilisation
Bacterial pellets were lysed as described in the Methods.
Briefly, the bacterial pellets were resuspended in Lysis
buffer and subjected to two cycles of sonication. Optimal
lysis of the bacterial pellet was achieved using 80 to
100 mL of Buffer A per 40 g of wet cell pellet. Addition
of DNase and protease inhibitors in the lysis buffer led
to a marked decrease in viscosity of the lysate and an in-
crease in solubility of inclusion bodies at the solubilisation
step. The inclusion bodies were collected by centrifuga-
tion, re-suspended in Buffer B and homogenised by a
combination of grinding with a pestle and mortar, son-
icating and pipette mixing; sonication was essential for
solubilisation of the inclusion bodies containing DI fu-
sion protein while the incubation temperature had no
impact on the solubilisation efficiency. Although using
more Buffer B had no impact on the solubilisation
yield, less concentrated preparations were less viscous,
facilitating subsequent procedures.
Purification of denatured DI by IMAC
Solubilised protein from the inclusion bodies was
purified by IMAC. DI fusion protein was eluted with
a gradient of pH and elution fractions were analysed
by SDS-PAGE (Fig. 3). The flow-through still con-
tained a limited amount of DI fusion protein (Lanes
2–4). Elution fractions showed a high concentration
of DI fusion protein at ~12 kDa as well as dimers
(~24 kDa) and multimers. In addition, a smaller spe-
cies (~10 kDa) was observed in the highly concen-
trated fractions (lanes 8–9) and could correspond to a
truncated or a degraded fragment of the fusion pro-
tein containing the N-terminal fusion tag.
Automated and gravity-driven drop columns were
both used and the automated method was preferred
due to scale of the purification. As expected an excess
of protein to the column resulted in preparations of
higher purity, as non-specific binding occurs when the
resin binding sites are not fully occupied. Introducing a
washing step using Buffer C, greatly reduced the
amount of impurities. Although impurities appear faint
on SDS PAGE gels, their absorption at 280 nm was suf-
ficient to be seen on a chromatograph. After this first
step of purification, the yield of purified denatured DI
fusion protein was around 125–150 mg of protein/ l of
medium when quantified in guanidine.
In vitro folding of DI fusion protein and IMAC purification
in native conditions
Two methods were compared for the in vitro folding
of DI fusion protein. The first method was stepwise
addition of ~1.0 mg (at a concentration of >10 mg/ml)
of denatured protein into 100 ml of Buffer E while
stirring at 4 °C; a total of 4 or 5 20-μl additions were
made. The second method was continuous automated
addition of protein using a syringe pump injecting the
DI fusion protein (at a concentration >10 mg/mL) in
the refolding buffer with a speed of 300 μL/h. The
automated continuous addition method resulted in
less protein aggregation after overnight incubation.
The maximum yield of soluble protein obtained by
continuous addition was 150 mg in 100 ml of Buffer E.
Denatured protein concentration during folding was
critical for the final yield of soluble protein, protein
folded at concentrations lower than 10 mg/mL aggre-
gated overnight.
The soluble DI fusion protein was then concentrated
and dialysed against Buffer F prior to IMAC-purification
in non-denaturing conditions. Avoiding high protein
concentrations at this stage was critical and a concentra-
tion for folded fusion protein of 2 to 2.5 fold was found
to be optimal. IMAC purification at this stage was very
successful for the removal of impurities (Fig. 3, 10 kDa
band), misfolded species and aggregates. Yield after
IMAC purification was between 50 and 75 mg per litre
of expression medium.
Fig. 4 An SDS PAGE gel depicting purified DI fusion protein before
FXa cleavage (Lane 2) and native DI and released fusion tag after
FXa cleavage (labelled accordingly)
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Fusion tag cleavage, purification of untagged DI and
endotoxin removal
Removal of the N-terminal tag was performed by addition
of restriction protease FXa to the fusion protein at a ratio
of 1:200 and incubation overnight at 22 °C. The digested
sample was then analysed by SDS-PAGE to confirm the
completion of the digestion (Fig. 4). After overnight diges-
tion the cleavage of the fusion protein was complete and
SDS-PAGE analysis showed 2 bands (Fig. 4, lane 2), corre-
sponding to the native DI (~8 kDa) and the fusion tag
(~6 kDa). A final step of purification by cation exchange
was performed and yielded >99 % pure monomeric DI as
judged by SDS-PAGE (Fig. 5c) and reverse phase chroma-
tography (Fig. 5a).
The concentration of protein for endotoxin removal
was 0.3–0.6 mg/mL and required the addition of 1 mM
extra CaCl2 for optimal yield. Endotoxin removal was
successful down to a level of < 1 EU/100 μg.
DI protein characterisation by mass spectroscopy and an
activity assay
DI was characterised by molecular weight determination
using MALDI-TOF mass spectroscopy. The mass spectrum
of the full-length protein displayed an m/z value of
7183.39 which is in agreement with the expected m/z
for the [M + H] + species of 7187.59, the mass error ob-
served is within the calibration limitation given the
small molecular weight of the protein.
Fig. 5 Characterisation of various DI batches by (a) RP-HPLC (C8) analysis, (b) MALDI-TOF and (c) SDS-PAGE Lane (1) Fusion protein, Lane (3) purified
DI and Lane (4) cleaved fusion Tag. Lane 2 is blank
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For the competitive inhibition ELISA, Serum samples
were obtained from six patients with APS. Three
were male, all were Caucasian and the mean (SD
13.9) age was 47. All six patients had suffered vascu-
lar thrombosis and two patients had suffered foetal
losses (1×2, 1×3). Importantly, serum from all six patients
had been found to have very high binding to β2GPI
in a solid phase ELISA assay. Figure 6 shows that of
six serum samples 4 were inhibited by 50 % or more and
two by 90 % (at 175 μg/ml patient 1–6: 73.3, 12.5, 11.3,
49.8, 13.4, 58.3 %).
Conclusions
Although other methodologies such as mammalian or
yeast expression may offer other benefits, such as post-
translational modification or secretion of soluble prod-
uct post-expression into medium, E.Coli offers many
advantages to the lab scale scientist. It allows simple
optimisation, is flexible, robust and can be translated to
a GMP environment.
In this paper we present a protocol for the preparation
of biologically active endotoxin-free DI expressed as
inclusion bodies in E. coli. Denatured DI was purified by
IMAC in guanidine hydrochloride, reduced with TCEP,
and folded in vitro by dilution into a buffer containing
0.6 M arginine as aggregation inhibitor and cysteine/
cysteine to promote the rearrangement of disulphide
bonds. After further purification and fusion tag removal,
the maximal yield was 50–75 mg per L of expression
media. This represents a 20-fold increase on previous
E. coli expression protocols for DI using in vivo folding
by periplasmic localisation (750 μg/L [36]) or in vitro
folding (~4 mg/L [37]).
The most vital stages of production, resulting in an in-
creased yield, were the bacterial pellet collection, folding
by continual injection and general automation. Replacing
LB with TB resulted in an increase in yield but primarily
due to an increased cell density rather than expression
itself. This increased cell density led to a thicker lysate
with more DNA, however, addition of DNAses to the lys-
ate and extensive washing of the bacterial pellet reduced
the viscosity and allowed a better purification process.
These washes also reduced endotoxin levels during the
purification process and resulted in a higher purity prod-
uct. The instigation of automated refolding via the syringe
pump increased yields by almost double and, when this
was combined with a slower and less harsh dialysis proto-
col, optimal yields were obtained. It is generally accepted
that aggregation occurs only between partially folded spe-
cies and that the presence of folded protein does not result
in increased aggregation [38], therefore gradual and
very slow addition of protein to folding buffer reduces
the effective concentration of unfolded species at any
given moment. Similarly, the same can be said of the
dialysis method. Automation of protein dilution also in-
creased yields minimising the number of handling steps
and human error. Interestingly, minimisation of the
total protein concentration during the dialysis steps
after folding also contributed to increase final protein
yield, perhaps because a fraction of the protein is still
partially unfolded at this stage.
Suggested future alterations to the method would in-
clude the introduction of an auto inducing culture [39].
Auto induction is a complex process but with the cor-
rect optimisation it may be used to increase the automa-
tion of the method, however, insufficient optimisation
risks a decrease in yield. Despite the positive benefits of
the new system we have described- increased expression,
efficient folding and high purity- the method does have
potential limitations. Preliminary attempts to use on-
column refolding failed as the protein fell out of solu-
tion and stripped the column suggesting that alterna-
tive methods of folding may not be suitable during
scale-up. On the other hand, only two methods of on-
column refolding were tried and both utilised a 5 mL
HisTrap IMAC column and further investigation with
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Fig. 6 Competitive Inhibition assay. Sera from six patients were tested using the purified Domain I at various concentrations. Values plotted are
an average of 2 experiments, SEM plotted above each point
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other chemistries may improve the technique. The major
limiting factor of the method is the large volume of buffer
required for folding. Similarly, the manual process of
grinding the cells is a drawback which could easily be
improved with equipment such as a French press. It is
therefore possible that further optimisation may im-
prove protein yield even more.
Further improvements to this methodology are neces-
sary for scaling up and automation. The major limitation
at this stage is the need to concentrate protein solutions
in several points during the process. The introduction of
an on-column protein folding method would ameliorate
this drawback. Unfortunately, our preliminary attempts
to implement such a methodology in the case of DI have
failed; presumably because of the very poor intrinsic
protein solubility of unfolded DI, which resulted in rapid
protein aggregation as soon as the concentration of
guanidine was reduced. An alternative and more promis-
ing approach would be to substitute protein concentra-
tion by centrifugal ultracentrifugation by ion exchange
chromatography or tangential flow filtration steps. An-
other change in the process required for scaling up is
the replacement of cell lysis by sonication for high pres-
sure disruption or by chemical methods. It is also pos-
sible that yields can also be increased by optimising and/
or altering the composition of the folding buffer, as a
great variety of potential aggregation inhibitors has been
described in the literature [38].
Regarding the activity of the protein, the inter patient
variability in susceptibility to inhibition by DI is likely
due to the fact that some patients possess anti-β2GPI
antibodies that interact with other domains (DII-V) and
is entirely consistent with results from previous experi-
ments using DI expressed in insect cells [29].
This methodology demonstrates a relatively simple, in-
expensive, reproducible and semi-automated bench top
method for the expression, folding and purification of
human DI up to a 0.1–0.15 g scale. This system opens
the possibility for the development of DI as a potential
therapeutic agent for APS.
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